PMV Pharmaceuticals, Inc. (PMVP): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No mundo da oncologia de precisão de ponta, os farmacêuticos PMV surgem como um inovador inovador direcionado à ilusória cenário da mutação p53. Ao alavancar o design avançado de medicamentos computacionais e uma plataforma de tecnologia proprietária, esta empresa de biotecnologia está revolucionando o tratamento do câncer por meio de estratégias terapêuticas altamente direcionadas. Sua abordagem única promete desbloquear terapias em potencial para cânceres anteriormente intratáveis, posicionando os produtos farmacêuticos PMV na vanguarda da medicina personalizada e oferecendo esperança a pacientes com mutações genéticas complexas que há muito desafiaram intervenções oncológicas tradicionais.

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com instituições de pesquisa acadêmica

A PMV Pharmaceuticals estabeleceu parcerias críticas de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco de colaboração	Ano iniciado
Universidade da Pensilvânia	Pesquisa de mutação p53	2019
Universidade Johns Hopkins	Estudos de Oncologia de Precisão	2020

Parcerias de desenvolvimento farmacêutico com organizações de pesquisa contratada

A PMV Pharmaceuticals colabora com organizações especializadas de pesquisa de contratos (CROs) para desenvolvimento de medicamentos:

• IQVIA - Gerenciamento de ensaios clínicos
• Parexel International - Suporte de pesquisa pré -clínica
• Medpace - Projeto de ensaios clínicos de oncologia

Acordos de licenciamento em potencial

As parcerias potenciais de licenciamento farmacêutico incluem:

Empresa farmacêutica	Área de colaboração potencial	Status
Merck & Co.	p53 terapias direcionadas	Discussões exploratórias
Bristol Myers Squibb	Tratamentos de oncologia de precisão	Negociações preliminares

Colaborações de pesquisa em oncologia de precisão

Parcerias de pesquisa de oncologia de precisão atuais:

• Memorial Sloan Kettering Cancer Center - perfil molecular
• Dana -Farber Cancer Institute - Desenvolvimento de terapia direcionada
• MD Anderson Cancer Center - Pesquisa genômica

Investimento em parceria de pesquisa total: US $ 12,4 milhões em 2023

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: Atividades -chave

P53 direcionou a pesquisa e desenvolvimento de drogas de câncer

A partir do quarto trimestre 2023, os PMV Pharmaceuticals se concentraram no desenvolvimento de terapias direcionadas para p53, com um orçamento específico de pesquisa de US $ 54,3 milhões dedicados à pesquisa e desenvolvimento de oncologia.

Foco na pesquisa	Investimento	Indicação alvo
Terapias específicas da mutação p53	US $ 28,7 milhões	Tumores sólidos avançados
Novas plataformas de oncologia de precisão	US $ 25,6 milhões	Tratamentos de câncer direcionados

Modelagem molecular e design de medicamentos computacionais

A PMV utiliza plataformas computacionais avançadas com um investimento anual de tecnologia de US $ 12,5 milhões em infraestrutura de modelagem molecular.

• Algoritmos avançados de aprendizado de máquina para modelagem de interação proteica
• Sistemas de computação de alto desempenho
• Ferramentas computacionais de biologia estrutural proprietária

Gerenciamento e execução de ensaios clínicos

Orçamento de desenvolvimento clínico para 2024: US $ 67,2 milhões, apoiando vários ensaios clínicos em andamento em diferentes indicações de oncologia.

Estágio clínico	Número de ensaios ativos	Alvo de inscrição do paciente
Fase 1	3 ensaios	180 pacientes
Fase 2	2 ensaios	250 pacientes

Processos de submissão e conformidade regulatórios

Orçamento de Assuntos Regulatórios: US $ 8,3 milhões, com equipe dedicada de 12 especialistas regulatórios gerenciando interações FDA e EMA.

Desenvolvimento terapêutico de oncologia de precisão inovadora

Investimento em P&D em plataformas de oncologia de precisão: US $ 41,9 milhões, visando mutações genéticas específicas em tratamentos contra o câncer.

• Abordagem terapêutica personalizada
• Design de medicamentos específicos para mutação
• Estratégias de tratamento orientadas por biomarcadores

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: Recursos -chave

Plataforma de tecnologia de segmentação por mutação p53 proprietária

A PMV Pharmaceuticals desenvolveu uma plataforma de tecnologia especializada focada em direcionar mutações específicas do câncer de p53. A partir do quarto trimestre 2023, a empresa identificou e caracterizou mais de 30 metas exclusivas de mutação p53 para possíveis intervenções terapêuticas.

Métricas da plataforma de tecnologia	Dados quantitativos
Metas exclusivas de mutação p53	Mais de 30 mutações identificadas
Investimento em pesquisa	US $ 12,5 milhões alocados em 2023
Aplicações de patentes	8 registros de patentes ativos

Equipe de pesquisa científica especializada

A empresa mantém uma equipe científica robusta com profunda experiência em oncologia.

• Pessoal de pesquisa total: 65 funcionários
• Pesquisadores de doutorado: 42
• Áreas de especialização: oncologia, biologia computacional, genética molecular

Infraestrutura avançada de descoberta de medicamentos computacionais

Capacidades computacionais: O PMV utiliza sistemas de computação de alto desempenho para modelagem molecular e descoberta de medicamentos.

Componente de infraestrutura	Especificação
Poder de processamento computacional	512 Teraflops
Capacidade de armazenamento de dados	2.5 Petabytes
Algoritmos de aprendizado de máquina	17 algoritmos de desenvolvimento personalizado

Portfólio de propriedade intelectual

A PMV Pharmaceuticals mantém uma estratégia de propriedade intelectual robusta para a nova terapêutica do câncer.

• Total de patentes ativas: 12
• Famílias de patentes: 5
• Cobertura geográfica: Estados Unidos, Europa, Japão

Financiamento de pesquisa e desenvolvimento

Fontes de financiamento apóiam iniciativas em andamento de pesquisa e desenvolvimento.

Fonte de financiamento	Valor (2023)
Venture Capital Investments	US $ 45,3 milhões
Subsídios do governo	US $ 7,2 milhões
Colaborações de pesquisa	US $ 3,5 milhões

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: proposições de valor

Terapêutica de oncologia de precisão Visando mutações específicas de p53

A PMV Pharmaceuticals se concentra no desenvolvimento de terapias direcionadas ao câncer, abordando especificamente as mutações no gene p53. A partir do quarto trimestre 2023, a empresa possuía 3 candidatos a medicamentos primários no desenvolvimento clínico direcionados a mutações específicas de p53.

Candidato a drogas	Tipo de mutação	Estágio clínico	TIPOS DE CABER LOVENDO
PC14586	Mutação p53 Y220C	Fase 1/2	Tumores sólidos
PC577	mutação p53 R273	Pré -clínico	Vários tipos de câncer

Abordagem inovadora para o tratamento do câncer

A abordagem de medicina de precisão do PMV tem como alvo alterações moleculares específicas em células cancerígenas. A avaliação do mercado da empresa em janeiro de 2024 foi de aproximadamente US $ 425 milhões.

Potencial para o desenvolvimento de terapias para cânceres anteriormente intratáveis

• População de pacientes endereçáveis ​​estimados para mutações p53: aproximadamente 50.000 pacientes anualmente
• Tamanho potencial do mercado para terapias de precisão p53: mais de US $ 1,2 bilhão
• Direcionamento exclusivo de mutações p53 anteriormente 'indrusáveis'

Metodologia avançada de design computacional de medicamentos

O PMV utiliza plataformas computacionais proprietárias para descoberta de medicamentos. As despesas de pesquisa e desenvolvimento em 2023 foram de US $ 86,3 milhões, representando um aumento de 22% em relação a 2022.

Terapias direcionadas com potencial para melhores resultados dos pacientes

Métrica	Valor
Investimento em P&D	US $ 86,3 milhões (2023)
Investimentos de ensaios clínicos	US $ 42,7 milhões (2023)
Portfólio de patentes	23 patentes concedidas

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa oncológica

A PMV Pharmaceuticals mantém o envolvimento direto por meio de interações direcionadas com os principais pesquisadores e instituições de oncologia. A partir do quarto trimestre de 2023, a empresa relatou 87 colaborações de pesquisa direta com centros de pesquisa acadêmica e médica.

Tipo de engajamento	Número de interações
Parcerias de pesquisa acadêmica	42
Colaborações do Centro Médico	35
Rede de Pesquisa Farmacêutica	10

Conferência Científica e Participação do Simpósio Médico

Em 2023, a PMV Pharmaceuticals participou de 17 principais conferências de oncologia, apresentando descobertas de pesquisa e se envolvendo com membros científicos da comunidade.

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Congresso da Sociedade Europeia de Oncologia Médica (ESMO)
• Simpósio de câncer de mama em San Antonio

Comunicação transparente do progresso do ensaio clínico

A empresa mantém a transparência por meio de atualizações regulares sobre os desenvolvimentos de ensaios clínicos. Em 2023, PMV publicado 6 Relatórios abrangentes de progresso do ensaio clínico.

Mecanismo de relatório	Freqüência
Apresentações de investidores	Trimestral
Bancos de dados de ensaios clínicos públicos	Semestral
Comunicados de imprensa	Conforme necessário

Colaborações do Grupo de Advocacia dos Pacientes

PMV Pharmaceuticals colabora ativamente com 12 organizações de defesa de pacientes focado em oncologia de precisão e terapias direcionadas.

• Rede Nacional de Sobreviventes de Câncer
• Coalizão de advocacia de medicina de precisão
• Fundação de Pesquisa de Câncer Genético

Publicação científica em andamento e compartilhamento de pesquisas

Em 2023, a empresa publicou 14 artigos científicos revisados ​​por pares em proeminentes periódicos de oncologia e medicina molecular.

Categoria de publicação	Número de publicações
Revistas revisadas por pares	14
Resumos da conferência	22
Apresentações de pesquisa	9

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: canais

Comunicação científica direta por meio de publicações de pesquisa

A PMV Pharmaceuticals publica pesquisas em revistas científicas revisadas por pares para comunicar os resultados da pesquisa.

Plataforma de publicação	Número de publicações (2023)
Biotecnologia da natureza	2 publicações
Descoberta do câncer	3 publicações
Terapêutica de câncer molecular	1 Publicação

Apresentações de relações com investidores e conferências financeiras

A Companhia utiliza conferências financeiras para comunicação de investidores.

Tipo de conferência	Número de apresentações (2023)
Conferência de Saúde JP Morgan	1 apresentação
Conferência de Saúde Cowen	1 apresentação
Conferência de Saúde Guggenheim	1 apresentação

Conferências da indústria de biotecnologia e farmacêutica

A PMV Pharmaceuticals se envolve em conferências específicas da indústria.

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Congresso da Sociedade Europeia de Oncologia Médica (ESMO)
• Sociedade de Imunoterapia do Câncer (SITC) Reunião Anual

Plataformas de comunicação digital

Canais digitais para comunicação corporativa e disseminação de informações.

Plataforma digital	Métricas de engajamento (2023)
Site corporativo	45.000 visitantes únicos
LinkedIn	12.500 seguidores
Twitter	8.200 seguidores

Interações da agência regulatória

Canais de comunicação formal com órgãos regulatórios.

• FDA Tipo B Discussões
• Interações de conselhos científicos da EMA
• Comunicações de aplicação de novos medicamentos para investigação (IND)

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Oncológica

A partir do quarto trimestre 2023, a PMV Pharmaceuticals possui parcerias de pesquisa colaborativa com 12 principais instituições de pesquisa de oncologia.

Tipo de instituição	Número de parcerias	Foco na pesquisa
Centros de pesquisa acadêmica	7	Pesquisa de mutação p53
Institutos de pesquisa do câncer	5	Oncologia de precisão

Empresas farmacêuticas e de biotecnologia

A PMV Pharmaceuticals estabeleceu colaborações estratégicas com 8 empresas farmacêuticas e de biotecnologia.

• Valor total de colaboração: US $ 157,5 milhões
• PODENTES PODENTES PAGAMENTOS: Até US $ 1,2 bilhão
• Acordos de licenciamento focados em terapias direcionadas à p53

Centros de Tratamento do Câncer

Engajamento de ensaios clínicos em 23 centros especializados de tratamento de câncer nos Estados Unidos.

Tipo central	Número de centros	Distribuição geográfica
Centros abrangentes de câncer	12	Cobertura nacional
Centros de oncologia especializados	11	Redes regionais

Pacientes com câncer específico de mutação p53

Análise da população de pacientes-alvo para câncer de p53, acionado por mutação:

• População estimada de pacientes: aproximadamente 50.000 pacientes anualmente
• Tipos de câncer primário: cânceres pulmonares, colorretais, ovarianos e pancreáticos
• Penetração potencial de mercado: 15-20% dos segmentos de pacientes identificados

Departamentos de pesquisa acadêmica

Pesquisa colaborativa Engajamentos com departamentos acadêmicos:

Tipo de departamento	Número de colaborações	Investimento em pesquisa
Oncologia Molecular	6	US $ 3,2 milhões
Pesquisa genética	4	US $ 2,7 milhões

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: estrutura de custos

Extensas despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a PMV Pharmaceuticals registrou despesas de P&D de US $ 72,3 milhões, representando uma parcela significativa de seus custos operacionais.

Ano fiscal	Despesas de P&D	Porcentagem do total de despesas
2022	US $ 72,3 milhões	68.4%
2021	US $ 63,1 milhões	65.7%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para PMV Pharmaceuticals em 2022 totalizaram aproximadamente US $ 45,2 milhões.

• Ensaios de fase 1: US $ 18,7 milhões
• Ensaios de fase 2: US $ 22,5 milhões
• Estudos pré -clínicos: US $ 4 milhões

Proteção e manutenção da propriedade intelectual

Os custos anuais de propriedade intelectual dos produtos farmacêuticos PMV foram de aproximadamente US $ 3,5 milhões em 2022.

Categoria IP	Custo anual
Registro de patentes	US $ 2,1 milhões
Manutenção de patentes	US $ 1,4 milhão

Recrutamento e retenção de talentos científicos

As despesas de pessoal para a equipe científica em 2022 totalizaram US $ 38,6 milhões.

• Salário médio da equipe científica: US $ 185.000
• Pessoal científico total: 208 funcionários
• Custos de recrutamento: US $ 1,2 milhão

Infraestrutura computacional e laboratorial avançada

Os investimentos em infraestrutura e tecnologia em 2022 foram de US $ 15,7 milhões.

Componente de infraestrutura	Investimento anual
Equipamento de laboratório	US $ 9,3 milhões
Sistemas computacionais	US $ 6,4 milhões

PMV Pharmaceuticals, Inc. (PMVP) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento terapêutico

A partir do quarto trimestre 2023, a PMV Pharmaceuticals possui acordos de licenciamento em potencial com os seguintes parâmetros financeiros:

Parceiro	Pagamento inicial potencial	Potencial marco
Pfizer	US $ 25 milhões	Até US $ 465 milhões

Bolsas de pesquisa e financiamento do governo

A PMV Pharmaceuticals recebeu financiamento de pesquisa das seguintes fontes em 2023:

• Institutos Nacionais de Saúde (NIH): US $ 2,1 milhões
• Concessão do Departamento de Defesa: US $ 1,5 milhão

Potenciais pagamentos marcantes de parcerias farmacêuticas

Estrutura de pagamento em potencial com parceiros farmacêuticos atuais:

Estágio de desenvolvimento	Valor do pagamento marco
Conclusão pré -clínica	US $ 10 milhões
Ensaios clínicos de fase 1	US $ 25 milhões
Ensaios clínicos de fase 2	US $ 50 milhões
Aprovação da FDA	US $ 100 milhões

Comercialização futura do produto

Potencial de receita projetado para candidatos terapêuticos principais:

Candidato a produto	Potencial estimado de receita anual
p53 terapias direcionadas	US $ 75 a US $ 120 milhões

Financiamento para investidores e aumentos de capital

Detalhes de aumento de capital para 2023-2024:

• Capital total levantado em 2023: US $ 85,4 milhões
• Caixa e equivalentes em dinheiro a partir do terceiro trimestre 2023: $ 189,3 milhões
• Dinheiro líquido usado em atividades operacionais: US $ 67,2 milhões

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Value Propositions

You're looking at the core reasons why PMV Pharmaceuticals, Inc. (PMVP) is positioned to capture value in precision oncology. The value proposition centers on a highly specific, first-in-class molecular intervention for a historically undruggable target.

The primary value is the First-in-class small molecule reactivating the p53 Y220C mutant protein. This molecule, rezatapopt (PC14586), is engineered as a structural corrector. It's designed to selectively bind to the pocket created by the p53 Y220C mutation, which effectively restores the normal, tumor-suppressing function of the p53 protein. This is a novel approach, as TP53 mutations are present in approximately half of all human cancers.

This mechanism supports a Tumor-agnostic therapy for advanced solid tumors with a high unmet need. The therapy targets the underlying mutation rather than the tumor's tissue of origin. Confirmed responses have been observed across eight distinct tumor types, including ovarian, lung, breast, and endometrial carcinoma, in patients whose tumors harbor the TP53 Y220C mutation and are KRAS wild-type. To be fair, there are currently no FDA-approved medicines that specifically target this p53 Y220C mutation, highlighting the significant unmet need. For the lead indication, platinum-resistant/refractory ovarian cancer, PMV Pharmaceuticals estimates the U.S. market opportunity alone is between $350 million and $420 million, based on about 1,700 second-line and later patients in the U.S. and five major European markets.

Clinical activity provides concrete evidence of this value, particularly in the lead indication. PMV Pharmaceuticals has Demonstrated 46% Overall Response Rate (ORR) in ovarian cancer cohort based on updated data. The clinical activity across the basket trial cohorts as of the September 4, 2025 data cutoff date shows compelling, rapid, and durable responses. Here's the quick math on the efficacy data from the Phase 2 pivotal portion:

Efficacy Metric	All Evaluable Patients (n=103)	Ovarian Cancer Cohort (n=44)
Overall Response Rate (ORR)	34%	46% (or 43%)
Median Duration of Response (mDoR)	7.6 months	8.0 months (or 7.6 months)
Median Time to Response	1.3 months	1.3 months

The therapy is also recognized for its potential to address this serious condition rapidly, as evidenced by the FDA Fast Track designation for advanced solid tumors. This designation was granted to rezatapopt for treating patients with locally advanced or metastatic solid tumors carrying the p53 Y220C mutation. This designation is intended to speed up development and review, helping the product reach patients sooner.

The company is actively investing to realize this value, with Research and Development (R&D) expenses at $18.2 million for the quarter ended September 30, 2025. This investment supports the ongoing enrollment, with plans to add an additional 20 to 25 platinum-resistant/refractory ovarian cancer patients by the end of the first quarter of 2026. Financially, PMV Pharmaceuticals ended Q3 2025 with $129.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway to the end of the first quarter of 2027.

The core value propositions can be summarized by what the drug delivers:

• First-in-class p53 Y220C structural corrector.
• Tumor-agnostic approach for advanced solid tumors.
• Observed 46% ORR in the lead ovarian cancer cohort.
• Rapid response time, median of 1.3 months.
• FDA Fast Track designation received.
• Targeting a mutation found in approximately 50% of all cancers.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Customer Relationships

You're looking at how PMV Pharmaceuticals, Inc. manages its key relationships, which for a clinical-stage biotech means heavy focus on investigators, regulators, and the investment community. This isn't about mass-market sales; it's about high-value, targeted engagement.

High-touch engagement with clinical trial investigators and sites is central, given the ongoing development of rezatapopt. The Phase 2 PYNNACLE trial is designed to enroll a total of 114 patients across five cohorts at approximately 60 sites globally. As of October 2024, more than 75% of these sites had been activated across the U.S., Europe, and Asia-Pacific. The engagement is also seen in investigator-initiated studies; for example, one study with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center was planned to enroll approximately 25 patients across two sites starting in Q1 2025. The data readouts themselves become key engagement points; an interim analysis reported in October 2025 included data from 103 evaluable patients, and a September 2025 webinar reviewed data for approximately 65 patients with at least 18 weeks of follow-up.

Metric	Value	Context/Date
Total Planned PYNNACLE Phase 2 Patients	114	PYNNACLE Trial Design
Total Planned PYNNACLE Sites	60	PYNNACLE Trial Design
Activated Sites (as of Oct 2024)	>75%	Of 60 planned sites
Investigator-Initiated Study Sites (AML/MDS)	2	Planned start Q1 2025
Patients in Oct 2025 Interim Analysis	103	Evaluated patients
Patients in Sep 2025 Webinar Analysis	~65	With at least 18 weeks follow-up

The focus on the p53 mutation means PMV Pharmaceuticals, Inc. is engaging with a specific scientific community. The company leverages these interactions to build credibility, for instance, by presenting data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025.

Transparent investor relations through conferences and one-on-one meetings is a consistent activity. Management, including the President and CEO, participated in at least two major investor conferences in the first half of 2025: the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025. Management also committed to one-on-one investor meetings around these events. Furthermore, an investor webinar was held on September 10, 2025, to review Phase 2 interim data. As of Q2 2025, PMV Pharmaceuticals ended the quarter with $148.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway to the end of 2026.

Regulatory dialogue with the US FDA for NDA pathway confirmation is guided by clinical milestones. PMV Pharmaceuticals anticipates submitting a New Drug Application (NDA) by the end of 2026. As of late 2025, the company has not received any FDA approvals for its therapy in the last two years. The data presented in October 2025, showing a 34% overall response rate (ORR) among 103 evaluable patients in the pivotal Phase 2 trial, directly informs this pathway discussion. The trial is designed such that this Phase 2 data will serve as the basis for the NDA, meaning no further Phase 3 studies are planned.

Regarding active participation in patient advocacy groups via the Avoca Consortium, the consortium itself held its 14th year summit in May 2025 (May 13-14, 2025), focusing on clinical trial quality and collaboration. The consortium also released its 2025 Avoca Industry Report on ICH E6(R3) Adoption & Implementation. Specific, verifiable data points confirming PMV Pharmaceuticals, Inc.'s direct membership or level of participation in the Avoca Consortium are not publicly available in the latest reports.

• CEO David H. Mack, Ph.D., and Chief Development Officer Deepika Jalota, Pharm. D., represented PMV Pharmaceuticals at the two listed 2025 investor conferences.
• The Q2 2025 net loss was $21.2 million.
• The Q1 2025 cash position was $165.8 million as of March 31, 2025.

Finance: draft 13-week cash view by Friday.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Channels

You're hiring before product-market fit, so the channels you use to get data and build credibility are everything right now. Here's the quick math on how PMV Pharmaceuticals, Inc. (PMVP) is currently reaching its key audiences, from clinical sites to the scientific community.

Global clinical trial network (PYNNACLE study) for drug delivery

The PYNNACLE Phase 2 monotherapy trial, evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation, is the primary channel for generating core clinical data. The trial was designed to enroll a total of 114 patients across five cohorts at approximately 60 sites globally. As of late 2024, more than 75% of these sites had been activated across the U.S., Europe, and Asia-Pacific. The company planned to submit a New Drug Application (NDA) by the end of 2026. An interim analysis webinar on September 10, 2025, reviewed data for approximately 65 patients with at least 18 weeks of follow-up. Of those patients, approximately 45% were in the ovarian cancer cohort. The company's ability to fund this network was supported by a cash, cash equivalents, and marketable securities balance of $148.3 million as of June 30, 2025, providing an expected cash runway to the end of 2026.

Metric	Value/Status
Total Planned PYNNACLE Phase 2 Patients	114
Approximate Total Trial Sites	60
Activated Sites (Late 2024)	>75%
Expected NDA Filing Date	End of 2026
Q2 2025 Interim Analysis Patients	Approx. 65
Ovarian Cancer Cohort Patients (Q2 2025 Interim)	Approx. 45% of interim group

Future specialty pharmacies and distributors post-regulatory approval

While PMV Pharmaceuticals, Inc. is pre-commercialization, the structure of the specialty drug market informs its future distribution channel strategy. Oncology is a key area of surge in the specialty drug pipeline. Optum Pharmacy Advisory actuaries estimate that per-member-per-month oncology spend will double between 2025 and 2027, ranging from about $8.24 to $15.24. For context on network setup, as of January 2025, 382 unique specialty drugs had a manufacturer-defined limited or exclusive specialty pharmacy network. In those exclusive networks, PBM-affiliated pharmacies had access to only one-quarter of the products.

Direct engagement with key opinion leaders (KOLs) in oncology

Direct engagement channels include scientific presentations where KOLs are often presenters or key attendees. For instance, the oral presentation of the pivotal PYNNACLE Phase 2 initial analysis at the 2025 AACR-NCI-EORTC International Conference on October 24, 2025, was presented by Alison M. Schram, M.D., of Memorial Sloan Kettering Cancer Center. Furthermore, the executive team, including David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, participated in one-on-one investor meetings alongside conference presentations in May and June 2025.

• CEO and CDO participation in one-on-one investor meetings: 2025 (May/June).
• KOL presentation of pivotal trial data at AACR-NCI-EORTC: October 24, 2025.
• Investigator-initiated study support with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center for AML/MDS.

Scientific publications and conference presentations (e.g., AACR-NCI-EORTC)

Scientific dissemination is a critical channel for validating the science behind rezatapopt. PMV Pharmaceuticals, Inc. had two abstracts accepted for presentation at the 2025 AACR-NCI-EORTC International Conference in Boston, MA, held October 22-26, 2025. The company also had a publication in ACS Medicinal Chemistry Letters in 2025, Volume 16, pages 34-39. The company's investor relations activities also function as a channel, with management participating in the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025.

• Publication in ACS Medicinal Chemistry Letters: 2025, Vol. 16, pp. 34-39.
• Oral Presentation at 2025 AACR-NCI-EORTC: Friday, October 24.
• Poster Presentations at 2025 AACR-NCI-EORTC: Friday, October 24 and Saturday, October 25.
• Investor Webinar to review Phase 2 data: September 10, 2025.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Customer Segments

You're looking at the core patient populations PMV Pharmaceuticals, Inc. is targeting with rezatapopt, which is a precision therapy for tumors carrying the TP53 Y220C mutation. The focus is sharp, going after a specific genetic signature across multiple cancer types.

Patients with locally advanced or metastatic solid tumors

The broad initial segment includes patients with advanced disease across various tumor types that share the specific genetic marker. Globally, p53 mutations are found in approximately half of all human cancers.

The current clinical evidence, as of the October 24, 2025 presentation at the AACR-NCI-EORTC International Conference, shows confirmed responses across eight tumor types in the Phase 2 PYNNACLE trial. These types include ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma.

The overall efficacy profile for this broad segment, based on the latest data cutoff, shows:

• Overall Response Rate (ORR) of 34% (35/103 evaluable patients).
• Median Duration of Response (DoR) of 7.6 months.
• Median Time to Response of 1.3 months.

Patients specifically harboring the TP53 Y220C mutation

This is the defined target population for rezatapopt. The Y220C mutation itself is found in roughly 1% of all cancers.

For the U.S. market, the total estimated annual patient pool harboring this specific mutation across all solid tumors is approximately 14,000 patients.

Within this segment, the ovarian cancer cohort is a key focus area for PMV Pharmaceuticals, Inc. as they plan their initial New Drug Application (NDA) submission.

Oncologists and specialized cancer treatment centers

Your customer base here isn't just the patient; it's the prescribing physician and the centers capable of administering and monitoring these specialized treatments. These are oncologists treating patients with advanced solid tumors who have undergone or are candidates for genetic testing confirming the TP53 Y220C mutation.

The trial structure itself points to the type of centers engaged. The Phase 2 PYNNACLE study is a registrational, single-arm basket trial, meaning it draws from centers experienced in running complex, multi-tumor trials. The data presented in late 2025 was from a study involving patients who had received prior standard of care treatments.

Platinum-resistant/refractory ovarian cancer patients (initial focus for NDA)

This specific subgroup is the initial regulatory priority. The need is substantial because approximately 80% of patients with advanced ovarian cancer relapse after first-line platinum therapies.

The market for platinum-resistant ovarian cancer in the US, EU4, UK, and Japan was valued at approximately USD 3,012 million in 2025.

PMV Pharmaceuticals, Inc. is targeting this group with a planned NDA submission by the first quarter of 2027. The company plans to enroll an additional 20-25 platinum-resistant/refractory ovarian cancer patients by the end of the first quarter of 2026 to support this submission.

The efficacy in this specific cohort, as of the latest update, is compelling compared to the standard of care, which has less than a 20% response rate in this population:

Tumor Type Cohort	Evaluable Patients	Overall Response Rate (ORR)	Median Duration of Response (DoR)
Ovarian Cancer	48	46% (22/48 patients)	8.0 months
Breast Cancer	12	17% (2/12 patients)	Data not specified
Endometrial Cancer	5	60% (3/5 patients)	Data not specified
Lung Cancer	19	21% (4/19 patients)	Data not specified

Financially, as of September 30, 2025, PMV Pharmaceuticals, Inc. held $129.3 million in cash, cash equivalents, and marketable securities, which provides an expected cash runway to the end of the first quarter of 2027, aligning with the planned NDA submission timeline for this key customer segment.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Cost Structure

You're looking at the cost side of PMV Pharmaceuticals, Inc. (PMVP) as they push their lead candidate through pivotal trials. For a clinical-stage biotech, the burn rate is almost entirely tied to R&D, and the numbers from late 2025 confirm that focus.

The biggest cost driver is definitely Research & Development (R&D) expenses, which hit $18.2 million for the third quarter ended September 30, 2025. That's up from $16.9 million in the same quarter of 2024. Honestly, this jump tells you exactly where the money is going: advancing rezatapopt in the PYNNACLE study.

General and administrative (G&A) expenses were lighter, coming in at $4.3 million for Q3 2025. That's actually a decrease from $4.9 million in Q3 2024, largely because of lower spending on stock-based compensation and general facility costs. It's good to see some operational costs ticking down while the core R&D spend rises.

Here's a quick look at the key operating expenses for the period:

Expense Category	Q3 2025 Amount (in millions USD)	Driver/Context
Research & Development (R&D)	$18.2	Advancement of rezatapopt program
General & Administrative (G&A)	$4.3	Reduced stock-based compensation

The R&D spend is heavily weighted toward external partners. You can expect significant costs here for Contractual Research Organizations (CROs) and the actual running of clinical trials. This is the price of admission for a company in Phase 2 development.

Regarding the clinical and manufacturing spend, the primary visible cost component is the clinical execution. Manufacturing and Chemistry, Manufacturing, and Controls (CMC) costs are inherent but are typically bundled or less detailed than the direct clinical spend in these quarterly releases. What we do know is the clinical activity:

• R&D increase driven by increased contractual research organization costs.
• Advancing the rezatapopt program through the PYNNACLE study.
• The study is a Phase 2 pivotal portion evaluating rezatapopt.
• Observed Overall Response Rate (ORR) of 34% across all cohorts (103 evaluable patients).
• Ovarian cancer cohort showed a 46% ORR among 48 evaluable patients.

The cash position reflects this burn rate; PMV Pharmaceuticals ended the third quarter with $129.3 million in cash, cash equivalents, and marketable securities. Finance: draft 13-week cash view by Friday.

PMV Pharmaceuticals, Inc. (PMVP) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PMV Pharmaceuticals, Inc. as of late 2025. Honestly, for a company at this stage, the revenue streams are almost entirely potential, backed by a solid balance sheet to fund operations until the next big inflection point.

Zero Product Revenue as of Late 2025 (Pre-Commercial Stage)

As of the third quarter ended September 30, 2025, PMV Pharmaceuticals, Inc. is firmly in the pre-commercial development phase. For the quarter, revenue was not reported, and consensus expectations were for $0.00. This means all operational funding currently comes from financing activities and investment income, not product sales.

Potential Future Revenue from Rezatapopt Product Sales Post-NDA Approval

The primary future revenue driver is the commercial sale of rezatapopt, a p53 reactivator. The company is targeting a New Drug Application (NDA) submission for platinum-resistant/refractory ovarian cancer in the first quarter of 2027. This timeline sets the earliest realistic expectation for product revenue generation post-approval, which is contingent on successful regulatory review.

Clinical data supports this future potential:

• Overall Response Rate (ORR) across all cohorts: 34% among 103 evaluable patients.
• ORR specifically in the ovarian cancer cohort: 46% among 48 evaluable patients.
• Median Duration of Response (DOR) in ovarian cancer cohort: 8.0 months.

Potential Upfront and Milestone Payments from a Future Licensing or Collaboration Deal

While PMV Pharmaceuticals, Inc. has not publicly disclosed specific, signed upfront or milestone payment figures as of late 2025, the progress in the Phase 2 pivotal portion of the PYNNACLE study serves as the key value driver for future partnership discussions. The company's current cash position is intended to fund operations through the NDA submission, but positive data strengthens the negotiating position for potential out-licensing deals or collaborations that would bring in non-dilutive capital via upfront payments and future milestone achievements.

Interest Income on Cash and Marketable Securities

This is the only current, tangible financial inflow stream supporting operations outside of financing. PMV Pharmaceuticals, Inc. ended the third quarter of 2025 with $129.3 million in cash, cash equivalents, and marketable securities. This balance provides an expected cash runway to the end of the first quarter of 2027. The company noted that this extended runway reflects both spend pacing and strong interest income. Here's the quick math on the cash position change:

Metric	Value as of September 30, 2025	Value as of June 30, 2025
Cash, Cash Equivalents, and Marketable Securities	$129.3 million	$148.3 million
Net Cash Used in Operations (9 months ended 9/30/2025)	$56.4 million	N/A

What this estimate hides is the exact dollar amount attributed to interest income versus the principal draw-down, but its inclusion in the runway extension narrative confirms it as an active, though secondary, revenue stream.

Finance: draft 13-week cash view by Friday.